The Hematologist

banner image

New Podcast

Drs. Kristen O'Dwyer, Jane Liesveld, and Courtney Jones have a conversation about how cysteine depletion targets leukemia stem cells through inhibition of electron transport complex II.

Play here
banner image

Does Your MDS Treatment Have Mettle?

Dr. Amy DeZern discusses the utility of iron chelation therapy in myelodysplastic syndromes.

Read more
banner image

Feature

Drs. Stephan Moll and Jori May discuss the Joint Commission's guidelines for reducing the likelihood of harm associated with use of anticoagulant therapy.

Read more
Current Issue Static Feature

Current Issue

November/December 2019
Volume 16, Issue 6

Read current issue

President's Column

Presidents Column - Kenneth AndersonProfessor and Chair of Medicine, Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI
Striking an Unwavering Balance
October 29, 2019

Dr. Silverstein wraps up a year of growth for ASH and previews hemostasis and thrombosis events at the annual meeting.

View all president's column articles

  • CAR T-cell Therapy: An Update on Coverage and Reimbursement
    August 14, 2019

    ASH continues to advocate for adequate coverage and reimbursement for chimeric antigen receptor T-cell (CAR-T) therapy. In early August, the Centers for Medicare and Medicaid Services (CMS) finalized policies impacting both reimbursement of and coverage for CAR-T therapy. The final Inpatient Prospective Payment System (IPPS) rule, published on August 2, and the final Decision Memo for CAR T-cell Therapy for Cancers, issued August 7.

  • 2018 ASH Advocacy Activities
    December 11, 2018

    ASH continues to increase its efforts to expand and enhance the Society’s reach. NIH funding, efforts to ensure patient access to drugs, and sickle cell disease were top priorities on ASH’s advocacy agenda in 2018.

  • 2018 ASH Advocacy Efforts Related to Sickle Cell Disease and Sickle Cell Trait
    December 11, 2018

    ASH continues to invest in and explore the important actions needed to make a significant difference in sickle cell disease (SCD) access to care, research, and global issues. Learn about the major advocacy-related initiatives undertaken by ASH in 2018.

  • 2018 ASH Advocacy Efforts to Ensure Patient Access to Care
    December 11, 2018

    In 2018, ASH worked to ensure patient access to care through a number of methods including ensuring drug access, pain management-related issues, and the Affordable Care Act.

View all Policy News